Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

Nsclc Clinical Trial

— CONCORDE  

Official title:

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03265496
• Other study ID #: CONCORDE-1510
• Status: Terminated
• Phase: N/A
• Start date: July 7, 2016
• Est. completion date: April 13, 2021

Study information

• Verified date: October 2021
• Source: Centre Oscar Lambret
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Condorde main objective is to evaluate the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed on ctDNA after liquid biopsy. EGFR status will be assessed by real time PCR (rtPCR), digital PCR (dPCR) and Next Generation Sequencing (NGS) in patients with chemotherapy naive lung carcinoma.

Description:

Newest therapeutic breakthrough are often based on molecular analysis of tumoral tissue before treatment initiation or after emergence of resistance. Tumoral tissue is commonly obtained by biopsy. However, tumor biopsy is an invasive, scarcely repeatable and costly technics. Moreover, tumor samples, obtained by biopsy, doesn't represent tumor heterogeneity and cannot inform about tumor evolution over time.

Recent improvement have been done in detection and characterization of blood circulating tumoral DNA (ctDNA). ctDNA reach regularly the blood stream after tumoral cell apoptosis or necrosis and could be extract and sequenced by some molecular biology technics such as real time PCR (rtPCR), digital PCR (dPCR) or next generation sequencing (NGS). Interesting, Several studies demonstrate that some genomic alterations of solid cancer can be characterized after sequencing of ctDNA. Other experiments pointed that ctDNA level could be linked to tumor stage and patient prognostic.

These progress lead to the development of a new non invasive method for extraction of ctDNA called liquid biopsy (LB). LB could be useful for monitor tumoral genotype, assess tumor response to treatment and detect residual tumor cells after curative treatment. Moreover LB could be an essential method for study of tumor cells molecular alterations mechanisms during targeted cancer therapies, when clinical resistance occurs.

Non-small cell lung cancer (NSCLC) is the most frequently diagnosticated type of lung cancer. Regular first line chemotherapy is based on the use of platinum salts. However, some mutations in the EGFR gene could add sensitivity of NSCLC to tyrosine kinase inhibitors such as gefitinib, erlotinib or afatinib. Consequently, the search for molecular mutations in genome of NSCLC cells is of prior interest for patients with clinically advanced NSCLC.

Recently, some studies demonstrate that mutational EGFR status of NSCLC was sharply correlated between tumoral tissue, obtained by classical biopsy, and ctDNA, collected by liquid biopsy.

These results provide promising data encouraging the use of LB for study of NSCLC ctDNA. However some experimentations are needed to ensure these data.

For that reason, CONCORDE clinical trial will evaluate the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. EGFR status will be assessed by real time PCR (rtPCR), digital PCR (dPCR) and Next Generation Sequencing (NGS) in patients with chemotherapy naive lung carcinoma.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: April 13, 2021
• Est. primary completion date: April 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years

• Metastatic lung carcinoma

• With: - EGFR gene mutation

• Or at least 2 predictive factors of addictive mutation (Women, non smocking or cessation > 3 years, Asiatic, lung adenocarcinoma)

• Eligible for 1st line treatment

• Performance status = 3

• Available tumor sample or tumor reachable for biopsy

• With informed and signed consent

• Affiliation to the National Social Security System

Exclusion Criteria:

• Previous radiotherapy treatment in months preceding initials samples

• Pregnant or breastfeeding women

• Patient not able to give consent or unwilling to provide consent

Related Conditions & MeSH terms

• Nsclc

Intervention

Procedure:
• Clinical exam
Clinical exam is performed before treatment start
• Liquid biopsy
Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
• Diagnostic exam
Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.

Drug:
• 1st line treatment
1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.

Procedure:
• tumor evaluation
Tumor evaluation will be performed every 3 cycles of chemotherapy

Biological:
• Biopsy
Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.

Locations

Country	Name	City	State
France	Centre Oscar Lambret	Lille
France	CHRU Lille	Lille

Sponsors (2)

Lead Sponsor	Collaborator
Centre Oscar Lambret	University Hospital, Lille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Mutation in ctDNA	To detect, at early stage, mutations on liquid biopsy. To identify, at early stage, mutations leading to treatment resistance by Next Generation Sequencing.	From Baseline to disease progression, up to 2 years
Other	expression pattern of tumor grade and resistance	To identify a predictive expression pattern for grade and treatment resistance of tumor by iterative sampling during treatment	From Baseline to disease progression, up to 2 years
Primary	Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At diagnostic. NGS.	For patient with mutant EGFR. Evaluate, by next generation sequencing at diagnostic, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.	Baseline
Secondary	Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At diagnostic. rtPCR.	For patient with mutant EGFR. Evaluate, by real time PCR at diagnostic, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.	Baseline
Secondary	Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At diagnostic. dPCR.	For patient with mutant EGFR. Evaluate, by digital PCR at diagnostic, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.	Baseline
Secondary	Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At disease progression. NGS.	For patient with mutant EGFR. Evaluate, by Next Generation Sequencing at disease progression, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.	From Baseline to disease progression, up to 2 years
Secondary	Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At disease progression. rtPCR.	For patient with mutant EGFR. Evaluate, by rtPCR at disease progression, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.	From Baseline to disease progression, up to 2 years
Secondary	Correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy. At disease progression. dPCR.	For patient with mutant EGFR. Evaluate, by dPCR at disease progression, the correlation between EGFR mutational status determined after tumor biopsy and EGFR mutational status analyzed after liquid biopsy.	From Baseline to disease progression, up to 2 years
Secondary	Incidence of oncogenic mutation for patients with predictive factors	To evaluate the incidence of oncogenic mutations in populations with clinical predictive factors of these mutations.	From Baseline to disease progression, up to 2 years
Secondary	Predictive value of ctDNA during treatment with EGFR targeting therapy.	To assess the predictive value of mutant ctDNA during treatment with EGFR targeting therapy.	From Baseline to disease progression, up to 2 years
Secondary	Mutations on ctDNA and tumor biopsy.	To search for mutations leading to treatment resistance on ctDNA and tumor biopsy at proved disease progression	From Baseline to disease progression, up to 2 years